{
    "organizations": [],
    "uuid": "4d4c663cecf8c193a08a16178c97472a32c9c3cf",
    "author": "",
    "url": "https://www.reuters.com/article/brief-nektar-therapeutics-announces-init/brief-nektar-therapeutics-announces-initiation-of-phase-1b-clinical-study-of-nktr-358-idUSFWN1SF0RP",
    "ord_in_thread": 0,
    "title": "BRIEF-Nektar Therapeutics Announces Initiation Of Phase 1B Clinical Study Of NKTR-358",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8, 2018 / 12:55 PM / Updated 22 minutes ago BRIEF-Nektar Therapeutics Announces Initiation Of Phase 1B Clinical Study Of NKTR-358 Reuters Staff 1 Min Read\nMay 8 (Reuters) - Nektar Therapeutics:\n* NEKTAR THERAPEUTICS ANNOUNCES INITIATION OF A PHASE 1B CLINICAL STUDY OF NKTR-358, A FIRST-IN-CLASS REGULATORY T CELL STIMULATOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage:",
    "published": "2018-05-08T15:53:00.000+03:00",
    "crawled": "2018-05-08T16:24:25.042+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "announces",
        "initiation",
        "phase",
        "1b",
        "clinical",
        "study",
        "reuters",
        "staff",
        "min",
        "read",
        "may",
        "reuters",
        "nektar",
        "therapeutic",
        "nektar",
        "therapeutic",
        "announces",
        "initiation",
        "phase",
        "1b",
        "clinical",
        "study",
        "regulatory",
        "cell",
        "stimulator",
        "patient",
        "systemic",
        "lupus",
        "erythematosus",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}